GLP2-T

Background

GLP-2 is a 33-amino-acid peptide hormone released by intestinal L-cells in parallel with GLP-1 from the same proglucagon precursor. Its physiologic role is to coordinate the post-meal intestinal growth response — villus elongation, increased nutrient absorption surface, and barrier reinforcement.

"GLP2-T" is a designation seen on some research-peptide vendor lists. It is not a standardized term in the published pharmacological literature. The likely interpretations are:

1. Native GLP-2 (33 aa, rapidly cleared by DPP-IV).
2. Teduglutide — a DPP-IV-resistant analog with a single alanine→glycine substitution at position 2. This is the approved drug Gattex.
3. A vendor-specific tagged or conjugated analog with undisclosed structure.

Sequence ambiguity is a real safety concern. Pharmacology described below refers to GLP-2 and teduglutide; whether a specific vendor product behaves the same depends on what it actually is.

Mechanism in depth

GLP-2 signals through the GLP-2 receptor (GLP-2R), a class B GPCR expressed primarily on enteric neurons and subepithelial myofibroblasts (not on enterocytes directly). Downstream effects include:

1. Crypt cell proliferation. IGF-1, EGF, and KGF release from subepithelial cells drives epithelial expansion.
2. Antiapoptotic signaling. Reduces enterocyte apoptosis under stress.
3. Tight-junction reinforcement. Increases expression of claudin-3, ZO-1; reduces permeability.
4. Mesenteric blood flow increase. Localized vasodilation contributes to mucosal nutrient absorption.

The same proliferative signal that produces clinical benefit in short bowel syndrome is the mechanistic basis for the cancer concern.

Human evidence

The validated dataset is for teduglutide:

• Jeppesen 2011 (STEPS, n=86, 24 weeks) — primary endpoint of ≥20% reduction in parenteral nutrition volume met by 63% of teduglutide patients vs 30% placebo in adult SBS.
• Pediatric extensions demonstrated similar effects in children with SBS.
• Long-term registries have refined the safety signal: cholecystitis, pancreatitis, and intestinal polyps occur at meaningful rates.

Outside SBS, human data for GLP-2 is sparse — small trials in inflammatory bowel disease, chemotherapy-induced mucositis, and post-bariatric absorption have shown signals but not led to indications.

Animal evidence

Rodent models replicate intestinal growth, barrier repair, and protection against chemotherapy/radiation enteritis. The colon polyp signal is also reproducible in long-term rodent studies — this is not a hypothetical concern, it is observed in animal carcinogenicity work.

Stack synergy

In SBS clinical practice teduglutide is layered onto parenteral nutrition with gradual taper. In research/peptide markets it is sometimes stacked with:

• BPC-157 — both promote GI healing via distinct mechanisms. Combination is anecdotal; no formal data.
• GLP-1 agonists — share the proglucagon precursor but distinct receptors. No specific interaction signal but the proliferative concern of GLP-2 may compound any unrelated GI risk.

Avoid stacking with IGF-1 or aggressive GH protocols without thought — IGF-1 is part of the GLP-2 proliferative cascade; adding exogenous IGF-1 may amplify the same cancer concern.

Open questions

• Is non-SBS use of GLP-2 (e.g., for general "gut health" or barrier support) supported by any clinical data? Effectively no — this is extrapolation from mechanism.
• What is the actual cancer risk magnitude with chronic exposure in healthy users? Teduglutide registry data is informative but the SBS population has different baseline risk than typical research-peptide users.
• What is the structure of vendor "GLP2-T" specifically? Without sequence confirmation, pharmacological inference is speculative.
• Does intermittent / cyclic dosing meaningfully reduce the proliferative risk while preserving benefit? This is the obvious question but no rigorous data exists.